First, we did not use NSCLC cell lines with EGFR L858R mutation, although we showed that ZEB1 was highly expressed in tumor specimens from NSCLC patients with EGFR L858R mutation after gefitinib resistance. Here, ZEB1 is linked to neoplasm.